肝癌药物市场规模- 按类型（HCC、胆管癌、肝母细胞瘤）、药物类别（化疗​​、标靶和免疫治疗）、给药途径（口服、注射）、药物类型（品牌、仿製药）、性别与预测，2024 - 2032

据世界卫生组织称，由于全球肝癌盛行率不断上升，过去二十年肝癌发病率增加了 75%，预计 2024 年至 2032 年肝癌药物市场的复合年增长率将达到 11.8%。 CDC 的报告称，这一增长主要归因于人口老化、饮酒量增加以及乙型肝炎和丙型肝炎的广泛发病，这些疾病影响全球超过 3.25 亿人。此外，生活方式因素，特别是肥胖和糖尿病，进一步增加了肝癌的发生率。因此，对更有效治疗方法的需求日益增长，从而刺激了先进肝癌药物的创新和商业化。

标靶疗法和免疫疗法的出现正在重塑肝癌治疗格局。例如，根据美国国家癌症研究所的数据，索拉非尼和纳武单抗等药物在临床试验中显示出显着的疗效。此外，在政府支持的支持下，製药实体增加了研发投资，正在加快药物发现和批准时间。这些进步不仅拓宽了治疗范围，也提高了肝癌药物的安全性和有效性基准，进一步推动市场扩张。

全球肝癌药物产业根据类型、药物类别、给药途径、药物类型、性别和地区进行分类。

由于发病率不断上升，特别是在儿科患者中，肝母细胞瘤类型预计到 2032 年将显着增长。肝母细胞瘤是儿童最常见的肝癌，需要与成人肝癌不同的专门治疗方案。随着对肝母细胞瘤的认识和早期诊断的提高，针对该患者群体的针对性和有效治疗的需求不断增长。製药公司越来越注重开发专门针对肝母细胞瘤的创新药物和治疗方案。再加上旨在了解和对抗肝母细胞瘤的研究工作和临床试验的加强，将有利于该细分市场的份额。

由于便利性和有效性，口腔肝癌药物产业领域将在预测期内获得巨大的吸引力。口服药物提供了静脉注射治疗的非侵入性替代方案，允许患者在家中服用，从而提高依从性并降低医疗成本。製药技术的进步已经生产出了高效的口服药物，具有更好的生物利用度和针对性的作用，最大限度地减少副作用并改善治疗结果。此外，口服製剂的便利性，加上支持其功效和安全性的强有力的临床证据，使它们成为患者和医疗保健提供者的首选。

到2032年，亚太地区肝癌药物市场将呈现强劲成长趋势，这得益于肝癌的高盛行率，特别是由于广泛的乙型和丙型肝炎感染以及饮酒和肥胖率上升。此外，中国和印度等国家不断增加的医疗保健支出和改善医疗基础设施正在促进更好地获得先进治疗。旨在加强癌症护理和研究的政府措施和支持政策也有助于市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 肝癌负担不断增加
    • 增加新疗法开发的研发投资
    • 人口老化加剧
    • 政府提高癌症意识的倡议
  • 产业陷阱与挑战
    • 与某些药物相关的副作用
    • 癌症治疗费用高
• 成长潜力分析
• 管道分析
• 监管环境
• 未来市场趋势
• 波特分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 肝细胞癌
• 胆管癌
• 肝母细胞瘤
• 肝转移
• 其他类型

第 6 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 化疗药物
• 标靶治疗药物
• 免疫治疗药物

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 口服
• 可注射

第 8 章：市场估计与预测：按药物类型，2021 - 2032

• 主要趋势
• 通用的
• 品牌化

第 9 章：市场估计与预测：按性别划分，2021 - 2032 年

• 主要趋势
• 男性
• 女性

第 10 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bayer AG
• Bristol-Myers Squibb Company
• Eisai Co., Ltd.
• Exelixis, Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Thermo Fisher Scientific Inc.

The liver cancer drugs market is estimated to register 11.8% CAGR during 2024 and 2032, driven by the escalating global prevalence of liver cancer, which has seen a 75% increase in incidence over the past two decades, according to WHO. This rise is primarily attributed to an aging population, heightened alcohol consumption, and the widespread incidence of hepatitis B and C, which affect over 325 million people worldwide, cites CDC report. Moreover, lifestyle elements, notably obesity and diabetes, are further bolstering the incidence of liver cancer. Consequently, there's a mounting need for more effective treatments, spurring the innovation and commercialization of advanced liver cancer drugs.

The advent of targeted and immunotherapies is reshaping liver cancer treatment landscape. For instance, as per National Cancer Institute, drugs like Sorafenib and Nivolumab have shown significant efficacy in clinical trials. Moreover, amplified R&D investments from pharmaceutical entities, bolstered by government backing, are expediting drug discovery and approval timelines. These strides not only broaden the treatment spectrum but also elevate the safety and efficacy benchmarks of liver cancer drugs, further propelling market expansion.

The global liver cancer drugs industry is classified based on type, drug class, route of administration, medication type, gender, and region.

The hepatoblastoma type segment is poised to significantly growth through 2032, due to increasing incidence, particularly among pediatric patients. Hepatoblastoma, the most common liver cancer in children, necessitates specialized treatment options that differ from those used for adult liver cancers. As awareness and early diagnosis of hepatoblastoma improve, there is a growing demand for targeted and effective therapies tailored to this patient population. Pharmaceutical companies are increasingly focusing on developing innovative drugs and treatment protocols specifically for hepatoblastoma. This, along with enhanced research efforts and clinical trials aimed at understanding and combating hepatoblastoma will favor the segment share.

The oral liver cancer drugs industry segment will gain substantial traction over the forecast period, owing to convenience and effectiveness. Oral medications offer a non-invasive alternative to intravenous treatments, allowing patients to take them at home, which improves compliance and reduces healthcare costs. Advances in pharmaceutical technology have produced highly effective oral drugs with better bioavailability and targeted action, minimizing side effects and improving treatment outcomes. Additionally, the convenience of oral formulations, coupled with strong clinical evidence supporting their efficacy and safety, makes them a preferred choice for both patients and healthcare providers.

Asia Pacific liver cancer drugs market will exhibit strong growth trends through 2032, backed by a high prevalence of liver cancer, particularly due to widespread hepatitis B and C infections and rising rates of alcohol consumption and obesity. Additionally, increasing healthcare expenditure and improving medical infrastructure in countries such as China and India are facilitating better access to advanced treatments. Government initiatives and supportive policies aimed at enhancing cancer care and research are also contributing to market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising burden of liver cancer
    • 3.2.1.2 Increasing R&D investments for the development of novel therapies
    • 3.2.1.3 Rising aging population
    • 3.2.1.4 Government initiatives to increase cancer awareness
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with certain medications
    • 3.2.2.2 High cost of cancer therapies
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Future market trends
• 3.7 Porters analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Hepatocellular carcinoma
• 5.3 Cholangiocarcinoma
• 5.4 Hepatoblastoma
• 5.5 Liver metastasis
• 5.6 Other types

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Chemotherapeutic agents
• 6.3 Targeted therapy drugs
• 6.4 Immunotherapy drugs

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Generic
• 8.3 Branded

Chapter 9 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Male
• 9.3 Female

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Amgen Inc.
• 11.3 AstraZeneca Plc
• 11.4 Bayer AG
• 11.5 Bristol-Myers Squibb Company
• 11.6 Eisai Co., Ltd.
• 11.7 Exelixis, Inc.
• 11.8 F. Hoffmann-La Roche Ltd.
• 11.9 Johnson & Johnson
• 11.10 Merck & Co., Inc.
• 11.11 Novartis AG
• 11.12 Sanofi SA
• 11.13 Thermo Fisher Scientific Inc.